VRDN Viridian Therapeutics, Inc.\DE Insider Trading

Fairmount Funds (director, 10% owner) invests $20M in VRDN shares near 52-week lows as stock rebounds from deeper weakness.

Fairmount Funds Management—a director and 10% beneficial owner of Viridian Therapeutics—deployed approximately $20 million to purchase over 1.1 million shares, expanding its position by roughly a third. This is the fund's fourth open-market purchase of VRDN stock in 36 months, signaling persistent conviction despite the company's unprofitable status and recent operational challenges (quarterly revenue cratered from full-year levels). The timing is noteworthy: the stock is trading well below its 52-week high after a sharp recent decline, but has recovered modestly over the past month—suggesting Fairmount may be accumulating during a period of relative stabilization after severe weakness. Fairmount's broader track record shows a strong preference for buying (16 prior purchases across all holdings versus only 3 sales in 36 months), though the fund's returns on prior open-market buys have been mixed, with short-term gains not translating to sustained long-term outperformance. Without measurable outcome data from Fairmount's three prior VRDN purchases, it remains unclear whether this repeated buyer has been right about the stock before—a material gap in assessing whether this fresh $20 million deployment reflects learned insight or persistent conviction despite mixed results.

Fairmount Funds Management LLC (Director) buys 454,545 shares of VRDN at $22.00 for $9,999,990.00

Fairmount Funds Management LLC, a director at Viridian Therapeutics, purchased 454,545 shares at $22.00 on 2025-10-23, increasing its holdings from 3,459,913 to 3,914,458 shares (+13.1%). The transaction occurred at a price 12.3% below the 52-week high of $25.71, and the stock has rallied +11.6% over the prior 30 days and +34.2% over 90 days. However, this director's prior open-market track record is mixed: 13 prior buys across other tickers showed an average 30-day return of +10.0% but an average 90-day return of -8.0%, with a 90-day win rate of only 33.33%. At VRDN specifically, the director's 2 prior purchases resulted in 0 instances of positive 90-day returns. Against this backdrop, the company's fundamentals remain challenged: Viridian reported quarterly revenue of $75,000.00 and a net loss of $-100,735,000.00, with annual revenue declining -3.8% year-over-year. The purchase represents a substantial capital commitment by the director, but the combination of poor historical timing on subsequent price movements and persistent unprofitability warrants close attention to whether this marks a genuine conviction threshold or a pattern continuation.

CEO Stephen F. Mahoney buys 21,400 shares at $23.33, accumulating first position as stock rallies +55.0% in 30 days amid severe revenue decline.

Stephen F. Mahoney, President and CEO of Viridian Therapeutics, purchased 21,400 shares at $23.33 on 2024-09-27, establishing an initial position. The transaction occurred as the stock was trading near its 52-week high of $23.82 (currently at $22.75, down -4.5% from the peak) and following a sharp 30-day rally of +55.0%. This open-market purchase by the company's top executive represents his first accumulated shareholding but warrants scrutiny given the company's financial deterioration: annual revenue contracted -82.3% and the company posted a net income of $-65.0M on quarterly revenues of just $72.0K. The timing of a CEO's initial equity acquisition while the stock rebounds strongly and the business experiences severe operational headwinds merits close monitoring of subsequent disclosures.

COO Thomas Beetham purchases 5,000 VRDN shares at $23.41, quintupling holdings to 6,000 shares amid 87.1% 90-day rally

Beetham, the Chief Operating Officer, purchased 5,000 shares at $23.41 on 2024-09-27, increasing his total holdings by 500.0% from 1,000 to 6,000 shares. This transaction occurs while the stock has surged 87.1% over the prior 90 days and 55.0% over the prior 30 days, trading near its 52-week high of $23.82. However, the company's fundamentals present a significant counterweight: Viridian reported revenue of $72,000.00 in its latest quarter with a net loss of $-65.0M over its most recent full fiscal year, coupled with an annual revenue decline of -82.3% year-over-year. The divergence between strong recent price momentum and deteriorating financial performance—particularly the severity of the revenue decline and persistent unprofitability—warrants examination of whether this accumulation reflects management conviction or occurs in isolation of broader insider trading activity and context.

Fairmount Funds Management LLC director purchased 1,600,000 shares of VRDN at $18.75 ($30.0M), raising stake by 86.7% to 3.45M shares post-transaction.

Fairmount Funds Management LLC (Director) deployed $30,000,000.00 to acquire 1,600,000 shares at $18.75, increasing its holdings by 86.7% from 1.85M shares to 3.45M shares. The transaction occurred while VRDN was trading 11.1% below its 52-week high of $23.82, and the stock has appreciated 36.7% over the prior 30 days and 73.9% over the prior 90 days. However, the company remains deeply unprofitable with a net income of $-65.0M against quarterly revenue of $72.0K, and annual revenue has contracted 82.3% year-over-year. Fairmount's cross-ticker track record shows 10 prior buys with an average 90-day return of -13.1% (33.33% win rate), and at VRDN specifically, the director's prior buy on 2024-01-22 generated a 90-day return of -30.5%, demonstrating weak timing accuracy at this ticker. The magnitude of this $30M purchase into a substantially enlarged position warrants scrutiny given the company's financial distress and the director's historical difficulty timing entries profitably, particularly at this ticker.